Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.51+0.04 (+0.24%)
Close on Nov 18, 2026Market cap $3.62BP/E –Yield –
Relay Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Relay Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$310.44M. For fiscal 2025 it was -$302.74M. The highest annual figure on record is -$55.80M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$302.74M | – |
| FY2024 | Dec 31, 2024 | -$372.47M | – |
| FY2023 | Dec 31, 2023 | -$373.00M | – |
| FY2022 | Dec 31, 2022 | -$299.28M | – |
| FY2021 | Dec 31, 2021 | -$364.70M | – |
| FY2020 | Dec 31, 2020 | -$55.80M | – |
| FY2019 | Dec 31, 2019 | -$84.05M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$90.82M | – |
| Q1 FY2026 | Mar 31, 2026 | -$78.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$60.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$80.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$76.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$84.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$84.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$96.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$100.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$90.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$92.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$73.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$106.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$101.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$72.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$85.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$77.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$62.72M | – |
| Q4 FY2021 | Dec 31, 2021 | -$67.72M | -293.6% |
| Q3 FY2021 | Sep 30, 2021 | -$60.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$193.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.41M | – |
| Q4 FY2020 | Dec 31, 2020 | $34.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.61M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.72M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.91M | – |
See a number that looks wrong?